TQB2102 for injection
Sponsors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Biliary Tract CancerBreast CancerGynecological TumorsHER2-positive Breast CancerNon-Small Cell Lung Cancer
Phase 1
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
CompletedNCT06115902
Start: 2023-11-17End: 2025-02-01Updated: 2026-07-08
A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer
RecruitingNCT06431490
Start: 2024-07-22End: 2029-12-01Target: 102Updated: 2026-04-08
Phase 2
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
RecruitingNCT06452706
Start: 2024-11-14End: 2028-06-30Target: 42Updated: 2024-11-19
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
RecruitingNCT06496490
Start: 2024-08-06End: 2026-12-31Target: 270Updated: 2025-11-20
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
RecruitingNCT06798207
Start: 2025-03-13End: 2026-11-30Target: 170Updated: 2025-07-18
Phase 3
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Active, not recruitingNCT06561607
Start: 2024-10-11End: 2028-12-01Target: 542Updated: 2026-09-10
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
RecruitingNCT07003074
Start: 2025-06-23End: 2030-07-31Target: 642Updated: 2025-06-25
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
RecruitingNCT07043725
Start: 2025-09-15End: 2029-09-01Target: 544Updated: 2026-03-27